Connect Biopharma Holdings (CNTB) Assets Average (2021 - 2026)

Connect Biopharma Holdings (CNTB) has reported Assets Average for 5 consecutive years, with $58.1 million the latest figure, recorded in Q1 2026.

• Quarterly Assets Average fell 40.12% year-over-year to $58.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.1 million (down 40.12% YoY) and the FY2025 annual result came in at $78.7 million, down 31.18% from the prior year.
• Assets Average fell to $58.1 million in Q1 2026 per CNTB's latest filing, from $61.7 million in the prior quarter.
• Over the last five years, Assets Average for CNTB reached as high as $262.5 million in Q2 2022 and fell as low as $58.1 million in Q1 2026.
• A 4-year average of $126.4 million and a median of $97.0 million in 2025 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average fell 10.76% — and 2026, when it slumped 40.12%.
• Year by year, Assets Average stood at $202.5 million in 2022, then plunged by 32.99% to $135.7 million in 2023, then sank by 54.53% to $61.7 million in 2025, then retreated by 5.91% to $58.1 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $58.1 million, $61.7 million, and $75.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.